#USA #San Diego #Class Action #Securities Fraud #Replimune Group

Overview

In a recent announcement, Robbins LLP, a renowned law firm specializing in shareholder rights, has reminded investors regarding important developments related to Replimune Group, Inc. (NASDAQ: REPL). The firm has brought to light a class action lawsuit filed against the clinical-stage biotechnology company over allegations of misleading statements related to the viability of its key clinical trial. This alert serves as a crucial reminder for shareholders who purchased Replimune securities between November 22, 2024, and July 21, 2025.

Background

Replimune Group, Inc. focuses on innovating and commercializing oncolytic immunotherapies aimed at treating cancer. However, significant concerns have come to light regarding the company’s IGNYTE trial, which has been a central aspect of its clinical studies. Investors are now facing potential uncertainties due to misleading information that it seems the company may have provided regarding the trial's progress and viability.

Allegations

The complaints state that during the class action period, key defendants at Replimune Group allegedly failed to disclose crucial aspects regarding the IGNYTE trial. Specifically:

• - Defendants are accused of exaggerating the trial's prospects, thus obscuring material issues that should have been known.
• - The FDA later deemed the trial inadequately controlled and therefore not viable for approval.

Consequently, investors were left with distorted notions about Replimune's business performance and growth potential.

On July 22, 2025, Replimune officially announced that it received a complete response letter (CRL) from the FDA, indicating that the agency could not approve its application for advanced melanoma treatment as the IGNYTE trial was deemed insufficiently controlled. Following this disclosure, the company’s stock price plunged significantly—dropping by $9.52 per share, representing a staggering 77.24% decline, ultimately closing at $2.80 per share.

Next Steps for Investors

Current shareholders of Replimune Group may have a unique opportunity to participate in this class action lawsuit. Individuals interested in being representative plaintiffs in the lawsuit must submit their filings to the court by September 22, 2025. This role typically involves directing the litigation on behalf of other class members.

However, it is essential to note that shareholders do not have to take direct action to remain eligible for recovery. If an investor prefers a more passive approach, they can constitute an absent class member, allowing them eligibility for any settlement outcomes.

About Robbins LLP

Robbins LLP has been a prominent name in shareholder rights litigation since its founding in 2002. The firm specializes in aiding shareholders to recover losses, improve corporate governance structures, and ensure accountability among company executives.

The firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a favorable outcome arises from the litigation. For those seeking updates on the class action or wishing to sign up for notifications regarding corporate misconduct resolutions, Robbins LLP provides a platform known as Stock Watch.

For further inquiries, potential class members can contact attorney Aaron Dumas via email or phone at (800) 350-6003.

Conclusion

The unfolding news surrounding Replimune Group highlights the complexities and difficulties investors often face in the biotechnology sector. With ongoing scrutiny and potential legal actions ahead, shareholders must remain informed and engaged in safeguarding their rights and investments. Robbins LLP is paving the way for those affected, ensuring that shareholder voices are heard amidst the complexities of corporate litigation.